Changchun Genescience Pharmaceutical Co., Ltd.

This early-stage trial tests a new drug called GenSci134 in healthy adults and patients with adult growth hormone deficiency. The main goal is to check safety and tolerability. Participants receive either the drug, a placebo, or an approved growth hormone for comparison.

This study tests a new drug called GenSci120 in 450 adults with moderate-to-severe rheumatoid arthritis who haven't improved with standard treatments. Participants receive either GenSci120, an existing drug (adalimumab), or a placebo for 14 weeks, followed by an extension period.…

This study tests a new drug called GenSci145 in people with advanced solid tumors that have a specific mutation in the PIK3CA gene. The trial has two parts: first, finding a safe dose, then seeing if it shrinks tumors. About 186 adults aged 18-75 will take the drug alone or with …

This early-stage trial is testing a new drug called GenSci098 in 76 adults with active thyroid eye disease (TED). The main goal is to check the drug's safety and how the body processes it at different doses. Participants will receive either the drug or a placebo as a shot under t…

This study tests a new weekly growth hormone injection (PEG-rhGH) against a standard daily shot in 72 short children born small for gestational age. The goal is to see if the weekly shot works as well or better for increasing height over 26 weeks. Participants are randomly assign…

This early-stage trial tests a new drug called GenSci143 in 180 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants receive GenSci143 by injectio…

This early-stage study tests a single injection of a new drug called GenSci098 in 24 adults with Graves' disease, a condition where the thyroid is overactive. The main goal is to check if the drug is safe and how the body handles it. Participants will be monitored for side effect…

This early-stage study tests a new medicine called GenSci136 in 48 healthy adults in China. The goal is to check if a single shot is safe and how the body processes it. This is a first step toward possibly treating autoimmune diseases, where the immune system attacks the body.

This study tests a new pill called GenSci128 in people whose advanced solid tumors have a specific change in the TP53 gene (Y220C). The main goals are to check the pill's safety, find the best dose, and see if it can shrink tumors. About 82 participants will take the pill by mout…

This early-stage study tests a new drug called GenSci140 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 170 adults in China will take part,…

This study tests two medicines, cabergoline and bromocriptine, to see which works better at lowering high prolactin levels in women aged 18 to 45. High prolactin can cause irregular periods, breast milk production, and fertility issues. The goal is to bring prolactin back to norm…

This early-stage study tests a new drug called GenSci139 in about 280 people with advanced solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is currently recruiting participants.

This study looks at how well a drug called nanocrystalline megestrol acetate works for cancer patients who have cachexia, a condition causing severe weight loss and appetite loss. About 495 adults with cancer and cachexia will take the drug and be monitored for up to 12 weeks. Th…

This study tests whether a new version of megestrol acetate can help people with advanced lung cancer maintain their appetite and body weight while undergoing chemotherapy and radiation. About 134 participants will receive either the study drug or a placebo alongside standard can…

This early-stage study tests a single injection of GenSci161 in 44 healthy adults aged 18 to 45. The goal is to check safety, side effects, and how the drug moves through the body. Participants are randomly assigned to receive either the drug or a placebo, and no one knows which …

This early-stage study tests the safety of a new drug called GS3-007a in 32 healthy Chinese adults aged 18-45. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The study also checks if food affects dr…

This study tests whether smoking changes how the body processes a single dose of GS1-144 tablets. It involves 24 healthy Chinese women aged 40-65 who are postmenopausal. Researchers will measure drug levels in the blood to see if smoking affects the drug's breakdown. The goal is …